Clinical Trials

Once weekly dalbavancin as effective as twice daily linezolid for complicated SSSIs

Published in Clinical Trials Week, December 26th, 2005

Once weekly treatment with dalbavancin is as effective as twice daily linezolid treatment for patients with complicated skin and skin structure infections (SSSIs).

"Dalbavancin, a novel lipoglycopeptide with a pharmacokinetic profile that allows weekly dosing, is active against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA)," scientists in Pennsylvania explained. The efficacy of dalbavancin for SSSI treatment was previously "demonstrated in a phase 2 study."

"In a phase 3 noninferiority study," conducted by L.E. Jauregui and colleagues working at Vicuron Pharmaceuticals, "patients with complicated SSSIs,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Clinical Trials Week

Source: Clinical Trials Week (2005-12-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry